ABN Amro Investment Solutions Purchases Shares of 6,794 Revolution Medicines, Inc. $RVMDMarket Beat·6 hours agoRVMD+0.25%JHG0.00%
Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price TargetTip Ranks·Jul 22 at 04:35 PMRVMD+0.25%
Revolution Medicines says FDA accepts daraxonrasib NDA for previously treated metastatic pancreatic cancerPUBT·Jul 22 at 03:11 PMRVMD+0.25%
16:26 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSSprnewswire·Jul 21 at 03:28 PMERAS-1.19%RVMD+0.25%
The Unbundling of Sectors: Decoding the Long Tail of the 2026 MarketGlobal Report·Jul 21 at 04:13 AMFLUX-7.72%CCK+2.96%
4 Health Care Stocks Whale Activity In Today’s Sessionbenzinga_article·Jul 17 at 12:35 PMTEM-7.22%RVMD+0.25%
21:44 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSSprnewswire·Jul 14 at 08:45 PMERAS-1.19%RVMD+0.25%
ERAS DEADLINE NOTICE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action LawsuitPR Newswire·Jul 9 at 05:05 AMERAS-1.19%
9 Health Care Stocks Whale Activity In Today’s Sessionbenzinga_article·Jul 8 at 12:35 PMTMO-0.71%DHR-0.52%
China’s biotech boom: RAS-targeted drugs challenge US dominanceSCMP·Jul 8 at 03:05 AM01276-1.82%600276-2.66%
Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSSPR Newswire·Jul 7 at 07:48 PMERAS-1.19%RVMD+0.25%
